EGL-001 for advanced solid tumors after immunotherapy
Part of Cancer clinical trials.
This trial tests a new drug called EGL-001 for people with advanced solid tumors that have already been treated with immunotherapy. The goal is to see if the drug is safe and effective against cancer that has not responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced cancer (solid tumor) that has spread or can't be removed by surgery, and standard treatments have stopped working or you can't have them.
- You have been treated with an immunotherapy drug (like a PD-1 or PD-L1 inhibitor) in the past.
- You are in fairly good health—able to do light work or normal activities (ECOG 0 or 1).
- You do not have an active autoimmune disease that requires strong immune-suppressing drugs.
- You have no active brain metastases, lung scarring, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an immunotherapy drug called GLS-012, alone and with another drug (GLS-010), in people with advanced solid cancers that have worsened despite standard treatment. It aims to see how well the treatment works and how safe it is, especially when given in different combinations.
This trial tests a new combination drug for people with advanced solid tumors, especially certain gynecologic cancers, that have not responded to standard treatments. The treatment aims to target a specific genetic marker (CCNE1) found in the tumor.
This trial tests different doses of a new drug (BI 3820768) in people with advanced solid tumors, specifically germ cell tumors, endometrial cancer, or ovarian cancer. The goal is to see if the drug is safe and how well it works.
This trial tests a new injection called CEL001 for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if it is safe and find the right dose.
This trial tests a new drug, IMGS-001, in people with advanced solid tumors that have grown back or not responded to standard treatments. It aims to find a safe dose and see if it helps shrink tumors.
This study tests a new experimental drug (NWY001) for people with advanced solid tumors that have stopped responding to standard treatments. It is a phase 1 trial, meaning it is early research to find the right dose and check for side effects.
Hear when a new Solid Tumor, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.